Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
mcRM153 is a mouse chimeric recombinant antibody (rat-mouse chimeric antibody) engineered with antibody-dependent cellular cytotoxicity (ADCC) activity. It is derived from the variable domain of the commercially available rat-derived anti-mouse CD153 antibody (clone RM153). Developed by Kyoto University and Epitope Science, mcRM153 targets CD153 (CD30 ligand), which is expressed on senescence-associated T cells (SA-T cells). By targeting CD153, the antibody depletes SA-T cells, suppresses tertiary lymphoid structure (TLS) formation, and reduces fibrosis and failed-repair proximal tubules in aged injured kidneys. It is being investigated in preclinical models for the treatment of chronic kidney disease (CKD).
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on mcRM153.